Philip Rask L. H.
- Country
- Denmark
- Department
- Department of Rheumatology
Research Overview
- High-Dose Thiamine Hydrochloride for Fatigue in Rheumatoid Arthritis: A Randomized, Double‑Blind, Placebo‑Controlled Trial
- Open-Label Extension Study Evaluating Long-Term Safety and Tolerability of Subcutaneous Secukinumab in Patients with Polymyalgia Rheumatica
- Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Secukinumab and Glucocorticoid Taper in Giant Cell Arteritis Patients
Data & Insights
Has run more than one trial at 70 of 181 partner sites.
Specializations
Rheumatology Focus
The investigator specializes in researching therapeutic approaches for psoriatic arthritis, with particular emphasis on understanding disease progression and treatment responses in both treatment-naïve and treatment-experienced patient populations.
- Active Psoriatic Arthritis Management
- Inflammatory Joint Disease
- Autoimmune Conditions
Their work encompasses evaluation of novel therapeutic interventions for inflammatory joint conditions.
Treatment Innovation
The investigator focuses on advancing therapeutic options for inflammatory arthritis, particularly examining innovative treatment approaches for different patient populations.
- Biologic-naïve Patient Care
- Treatment-experienced Patient Management
- Novel Therapeutic Assessment
Their research interests include evaluating treatment efficacy in various patient subgroups.
Clinical Assessment
The investigator specializes in evaluating symptom reduction and therapeutic responses in inflammatory joint conditions, with expertise in assessing treatment outcomes.
- Disease Activity Monitoring
- Treatment Response Assessment
- Clinical Outcomes Evaluation
Their work involves comprehensive assessment of therapeutic interventions in rheumatic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.